Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction
- PMID: 9193380
- DOI: 10.1016/S0140-6736(97)01234-8
Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction
Abstract
Background: Epidemiological data suggest that the intake of antioxidants such as alpha-tocopherol (vitamin E) and beta-carotene has an inverse correlation with the incidence of coronary heart disease. The results from clinical trials of antioxidant supplementation in people with known coronary heart disease are inconclusive.
Methods: We studied the frequency of major coronary events in 1862 men enrolled in the alpha-tocopherol beta-carotene Cancer Prevention Study (smokers aged between 50 and 69 years) who had a previous myocardial infarction. In this randomised, double-blind. placebo-controlled study, men had received dietary supplements of alpha-tocopherol (50 mg/day), beta-carotene (20 mg/day), both, or placebo. The median follow-up was 5.3 years. The endpoint of this substudy was the first major coronary event after randomisation. Analyses were by intention to treat.
Findings: 424 major coronary events (non-fatal myocardial infarction and fatal coronary heart disease) occurred during follow-up. There were no significant differences in the number of major coronary events between any supplementation group and the placebo group (alpha-tocopherol 94/466; beta-carotene 113/461; alpha-tocopherol and beta-carotene 123/497; placebo 94/438 [log-rank test, p = 0.25]). There were significantly more deaths from fatal coronary heart disease in the beta-carotene (74/461, multivariate-adjusted relative risk 1.75 [95% CI 1.16-2.64], p = 0.007) and combined alpha-tocopherol and beta-carotene groups (67/497, relative risk 1.58 [1.05-2.40], p = 0.03) than in the placebo group (39/438), but there was no significant increase in the alpha-tocopherol supplementation group (54/466, relative risk 1.33 [0.86-2.05], p = 0.20).
Interpretation: The proportion of major coronary events in men with a previous myocardial infarction who smoke was not decreased with either alpha-tocopherol or beta-carotene supplements. In fact, the risk of fatal coronary heart disease increased in the groups that received either beta-carotene or the combination of alpha-tocopherol and beta-carotene; there was a non-significant trend of increased deaths in the alpha-tocopherol group. We do not recommend the use of alpha-tocopherol or beta-carotene supplements in this group of patients.
Comment in
- ACP J Club. 1998 Jan-Feb;128(1):7
-
Anti-oxidant therapy for ischaemic heart disease: where do we stand?Lancet. 1997 Jun 14;349(9067):1710-1. doi: 10.1016/S0140-6736(97)22024-6. Lancet. 1997. PMID: 9193375 No abstract available.
-
Antioxidants and ischaemic heart disease.Lancet. 1997 Aug 30;350(9078):667; author reply 668. doi: 10.1016/S0140-6736(05)63362-4. Lancet. 1997. PMID: 9288073 No abstract available.
-
Antioxidants and ischaemic heart disease.Lancet. 1997 Aug 30;350(9078):667; author reply 668. doi: 10.1016/S0140-6736(05)63363-6. Lancet. 1997. PMID: 9288074 No abstract available.
-
Antioxidants and ischaemic heart disease.Lancet. 1997 Aug 30;350(9078):667-8. doi: 10.1016/s0140-6736(05)63364-8. Lancet. 1997. PMID: 9288075 No abstract available.
-
GISSI-Prevenzione trial.Lancet. 1999 Oct 30;354(9189):1555; author reply 1556-7. doi: 10.1016/S0140-6736(05)76583-1. Lancet. 1999. PMID: 10551520 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
